Search research articles
Contact Us
Filters
Showing results (81-90 of 117) with videos related to
Page
of 12
Sort By:
Journal of Gastroenterology and Hepatology
|
January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver Cancer
|
May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Reports (Hoboken, N.J.)
|
April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancers
|
September 9, 2023
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology
|
February 3, 2025
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient
Atsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
Atsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 117) with videos related to
Sort By:
Page
of 12
Journal of Gastroenterology and Hepatology
|
January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver Cancer
|
May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Reports (Hoboken, N.J.)
|
April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancers
|
September 9, 2023
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology
|
February 3, 2025
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient
Atsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
Atsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Page
of 12